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http://dx.doi.org/10.1016/j.ccr.2013.01.011SUMMARYMost patients with acute lymphoblastic leukemia (ALL) fail current treatments highlighting the need for better
therapies. Because oncogenic signaling activates a p53-dependent DNA damage response and apoptosis,
leukemic cells must devise appropriate countermeasures. We show here that growth factor independence 1
(Gfi1) can serve such a function because Gfi1 ablation exacerbates p53 responses and lowers the threshold
for p53-induced cell death. Specifically, Gfi1 restricts p53 activity and expression of proapoptotic p53 targets
such as Bax, Noxa (Pmaip1), and Puma (Bbc3). Subsequently, Gfi1 ablation cures mice from leukemia and
limits the expansion of primary human T-ALL xenografts in mice. This suggests that targeting Gfi1 could
improve the prognosis of patients with T-ALL or other lymphoid leukemias.INTRODUCTION
Many patients with acute lymphoblastic leukemia (ALL) and
lymphoma die of tumor relapse (Go¨kbuget and Hoelzer, 2009).
Experiments with mouse models have shown that T-ALL-like
diseases can be accelerated by the overexpression of the tran-
scriptional repressor growth factor independence 1 (Gfi1), whichSignificance
Chemotherapy is nonspecific and highly toxic, damaging both
dramatic side effects from standard treatments. Molecular-ba
broad applicability due to the heterogeneity of oncogenic path
that ablation of Gfi1 broadly leads to lymphoid tumor regression
We demonstrate that Gfi1 limits the proapoptotic functions o
p53-dependent proapoptotic responses driven by oncogeni
uniquely susceptible to Gfi1 inhibition. Thus, in combination wit
cytotoxic doses, which would benefit patients directly.
200 Cancer Cell 23, 200–214, February 11, 2013 ª2013 Elsevier Inc.is a well-established nuclear zinc finger protein and regulator of
lymphoid development (Gilks et al., 1993; Zo¨rnig et al., 1996;
Li et al., 2010; Pargmann et al., 2007; Spooner et al., 2009;
Yu¨cel et al., 2003). Germline Gfi1 deletion in mice modestly
reduces thymic cellularity, with an accumulation of cells between
double-negative 1 (DN1) and DN2 stages as well as a skew from
CD4+ to CD8+ (Yu¨cel et al., 2003). In contrast, the thymus ishost and tumor tissues. Even when effective, patients suffer
sed targeted therapies have shown great promise but lack
ways mutated during transformation. Here, we demonstrate
and host survival independent of the transforming pathway.
f the endogenous gatekeeper p53. Gfi1 inhibition amplifies
c stress; consequently, transformed lymphoid tissues are
h current therapies, Gfi1 inhibitionmay allow the use of lower
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Gfi1 and Lymphoid Leukemiarelatively normal when Gfi1 is deleted after the DN stage (Zhu
et al., 2006), which suggests that Gfi1 mainly acts during early
steps of T lymphopoiesis. Gfi1’s ability to accelerate leukemo-
genesis in mice and its function in lymphoid development
prompted us to explore the role of Gfi1 ablation in the initiation
or maintenance of lymphoid malignancies.
RESULTS
GFI1 Is Associated with a Subgroup of Human T-ALL
and Accelerates NOTCH1-Induced T-ALL in Mice
Although the oncogenic impact of high-level Gfi1 expression in
murine T cell leukemogenesis is well established, an association
of GFI1 with human T-ALL has not been clearly shown. Because
over 50% of human T-ALL displays mutated NOTCH1 (Weng
et al., 2004) or Notch1 regulatory proteins (O’Neil et al., 2007;
Thompson et al., 2007) resulting in overexpression of Notch1
target genes (Palomero et al., 2006; Sharma et al., 2006; Weng
et al., 2006), we performed hierarchical clustering of microarray
data from independent cohorts of patients with T-ALL using
NOTCH1 mutation status (Ferrando et al., 2002), Notch1 target
gene activation (Palomero et al., 2006; Van Vlierberghe et al.,
2008), or early T cell precursor (ETP)-ALL diagnosis (Coustan-
Smith et al., 2009) and examined GFI1 expression (Figures 1A
and 1B; Figures S1A–S1F available online).
We observed that patients with ETP-ALL had low levels of
GFI1 expression compared to those with a positive NOTCH1
signature (Figures 1B, S1D, and S1E), suggesting a functional
role for Gfi1 in NOTCH1-dependent human T-ALL. However,
GFI1 is unlikely a Notch1 target because intracellular Notch1
(ICN) does not occupy the GFI1 locus nor was GFI1 expression
altered by g-secretase inhibitors (GSIs) based on our own results
as well as published data (Figure S1F) (Margolin et al., 2009;
Medyouf et al., 2011). Also, we can show that mice transplanted
with bone marrow (BM) cells overexpressing ICN and Gfi1
developed leukemia faster than mice transplanted with cells
only overexpressing ICN (Figures S1G–S1I), corroborating
previous reports on the function of Gfi1 in T cell leukemogenesis
(Schmidt et al., 1998; Zo¨rnig et al., 1996) and extending it to
human ICN-mediated T-ALL.
Gfi1 Deletion Delays the Development of T-ALL
To test whether ablation of Gfi1 could inhibit the onset of T-ALL,
we used five different mouse models, in which we could tempo-
rally delete Gfi1. First, we transplanted ICN-expressing BM cells
from mice carrying a tamoxifen (OHT)-inducible Rosa26 Cre-
recombinase transgene (CreERT2) (Hameyer et al., 2007) enabling
inducible deletion of floxed Gfi1 alleles (Gfi1f/f) (Horman et al.,
2009; Velu et al., 2009) (Figure 1C). Although vehicle-treated
animals died within 66 days, OHT-treated recipients developed
leukemia within 87 days with similar T-ALL characteristics
(Figures 1C–1F). However, all tumors emerging after OHT
treatment had intact Gfi1 alleles (Figure 1D), suggesting that
ICN-induced T-ALL selects for Gfi1.
To confirm this, we used a T cell-specific Cre transgene
(LckCre+) and Gfi1f/D transgenic mice, in which Rosa26 locus-
mediated expression of ICN and EGFP is blocked by a floxed
STOP cassette (Rosa ICNLSL) (Murtaugh et al., 2003). We
injected these mice with N-ethyl-N-nitrosourea (ENU), whichCinduces T cell leukemia and shortens the latency of leukemo-
genesis (Kundu et al., 2005; Yuan et al., 2001). Approximately
50% of all tumors arising in LckCre+;Rosa ICNLSL;Gfi1+/+ mice
were EGFP+ (i.e., expressing ICN and Gfi1, Figures S1J and
S1K). However, ENU-induced tumors that arose in LckCre+;
Rosa ICNLSL;Gfi1f/D mice were always EGFP (i.e., ICN and
Gfi1 wild-type, Figure S1K,), also suggesting that ICN-mediated
tumorigenesis selects for Gfi1. In yet another Notch-driven
leukemogenesis model, in which constitutive absence of Gfi1
was coupled with a CD4 promoter-driven mutant Notch1 trans-
gene (Notch1DCT; Priceputu et al., 2006), T-ALL development
was substantially decreased and delayed (Figures 1G–1I).
To explore the impact of Gfi1 loss in mouse models of T-ALL
that are not initiated by Notch, we either infected Gfi1+/+ and
Gfi1/ newborn mice with Murine Moloney Leukemia (MMLV)
(Scheijen et al., 1997) or injected adolescent mice with ENU.
All MMLV-infected Gfi1+/+ mice developed lymphoid malignan-
cies, whereas only 40% of MMLV-infected Gfi1/ mice did.
The remainingmicewere censored due to neurological problems
consistent with reports on olderGfi1/mice (unpublished data).
Notably, Gfi1/ lymphoid malignancies were significantly less
robust than Gfi1+/+ tumors (Figures 1J–1L). Similarly, >85% of
the ENU-injected Gfi1+/+ mice, but only 20% of Gfi1/ mice,
developed T cell leukemia (Figure S1L); the remaining mice
succumbed to ENU-induced toxicity. As in other models, ENU-
initiated Gfi1/ tumors developed slower and were significantly
less robust than Gfi1+/+ tumors (Figures S1L–S1N). Neither
Gfi1+/+ nor Gfi1/ ENU-induced tumors were found to harbor
Notch1 mutations in the HD or PEST domain (Table S1). Thus,
results from these five independent T-ALL models, initiated by
various oncogenic pathways, led us to conclude that ablation
of Gfi1 delays, impedes, or is counterselected during T-ALL
formation.
T-ALL Disease Maintenance Is Gfi1 Dependent
Mx1-Cre+;Gfi1f/f or Gfi1f/f mice were treated with ENU to elicit
T cell leukemia. After 50 days, both groups were injected with
pIpC (Horman et al., 2009). All Gfi1f/f mice developed T-ALL,
but Mx1-Cre+;Gfi1f/f mice separated into two different
subgroups following pIpC injection. One subgroup remained
healthy until the study was terminated (Figure 2A, Mx1-Cre+;
Gfi1f/f, full excision) or died of ENU toxicity. The second
subgroup displayed partial Gfi1 deletion and succumbed to
T cell leukemia similar to ENU/pIpC-treated Gfi1f/f mice (Fig-
ure 2A, Mx1-Cre+;Gfi1f/f partial excision).
To investigate whether loss of Gfi1 was causing tumor regres-
sion or preventing tumor formation, we used ultrasound imaging.
Upon detection of a tumor (Figure 2B),Gfi1 deletion was induced
with pIpC. All ENU-induced tumors inGfi1f/fmice clearly showed
increases in tumor size, whereas tumors that developed inMx1-
Cre+;Gfi1f/f animals showed variable changes in size (Figures 2C
and S2A). Following pIpC injection, disease-free survival, tumor
growth, and blast cell detection all directly correlated with the
degree of Gfi1 deletion in the tumor (Figures 2B, 2C, and S2B)
because we found that Gfi1 deletion was incomplete in tumors
that progressed but was complete in tumors that regressed
(Figure S2A).
We verified this observation in a second T-ALL model, in
which disease was induced by Notch1 activation andancer Cell 23, 200–214, February 11, 2013 ª2013 Elsevier Inc. 201
Figure 1. Gfi1 Associates with NOTCH1 in Human T-ALL, and Deletion Delays the Development of Disease
(A) Heatmap of expression of published Notch1 target genes used to classify gene expression array data from 55 patients with T-ALL (GSE8879) into two groups:
‘‘Negative Notch Signature’’ (left), and ‘‘Positive Notch Signature’’ (right). ETP-ALL diagnosis is designated by an ‘‘X.’’
(B) Quantification of relative expression of NOTCH1,GFI1, and Notch1 target genes HES1,MYC, NOTCH3, CR2, IGF1R, and E2F5 in 55 patients with T-ALL with
either a ‘‘Negative Notch Signature’’ (gray) or a ‘‘Positive Notch Signature’’ (black).
(C) Top view shows RosaCreERT2;Gfi1f/f BM cells that were transduced with vectors expressing ICN and then transplanted. Mice were given vehicle or tamoxifen
to induce Cre activity. Bottom view is a Kaplan-Meier curve.
(D) PCR genotype analysis of theGfi1 locus in control tissues (Gfi1D/D,Gfi1+/D,Gfi1+/+) and in representative tumors frommice either treated with vehicle or OHT.
FLOX, Gfi1f allele; +, the wild-type allele; D, deleted allele.
(E and F) Spleen weights (E; n = 6 each group) and flow cytometric analysis of thymic tumors (F, top panels) and spleen sections with H&E (F, bottom panels)
collected during postmortems from indicated transplant groups.
(legend continued on next page)
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sound and upon tumor detection, treated with pIpC (Figure 2D).
Although all pIpC-injected Notch1DCT;Gfi1f/f mice died, all
pIpC-injected Notch1DCT;Mx1-Cre+;Gfi1f/f tumors with
complete deletion of Gfi1 regressed, and the mice survived
(Figures 2D–2F). This regression also correlated with lower
numbers of blast cells in the blood of pIpC-treated
Notch1DCT;Mx1-Cre+;Gfi1f/f mice compared to Notch1DCT;G-
fi1f/f controls (Figure S2C).
Next,Gfi1f/f orMx1-Cre+;Gfi1f/D tumor cells were transplanted
into syngeneic recipients. In recipients that did not receive pIpC,
only tumors with an intact floxed Gfi1 allele emerged (data not
shown). However, when recipient mice were treated with pIpC,
all mice that received Gfi1f/f tumors died, whereas mice
receiving Mx1-Cre+;Gfi1f/D tumors survived tumor free (Fig-
ure 2G). To demonstrate that loss of Gfi1 specifically leads to
tumor regression in a cell-autonomous manner, we inhibited
Gfi1 function in three Tal1-transformed murine T-ALL cell lines
(Cullion et al., 2009) by overexpressing a dsRed-marked Gfi1
dominant-negative mutant (Gfi1N382S) (Horman et al., 2009;
Person et al., 2003; Zarebski et al., 2008). Two days after the
initial measurement of transduction, and in contrast to empty
vector-transduced cells, only 15%–20% of cells transduced
with dsRed+ Gfi1N382S-expressing vectors were still dsRed+
(Figure 2H).
To determine the clinical potential of targeting Gfi1, we in-
jected Gfi1f/f and Mx1-Cre+;Gfi1f/f mice (CD45.2+) with ENU,
waited 50 days to allow tumor initiation, and then treated with
pIpC to delete Gfi1. Four weeks after the first pIpC injection,
both groups of mice were sublethally irradiated and trans-
planted with syngenic CD45.1+ BM cells (BMT) to prevent BM
failure associated with ENU (Figures 2I and 2J). The combina-
tion therapy was not sufficient to cure the mice of T-ALL
because 80% of ENU-treated Gfi1f/f mice still succumbed to
disease (one died of nontumor-related reasons). However,
when therapy was combined with Gfi1 deletion, complete
tumor remission was observed in every transplant recipient
(Figures 2I and 2J). Taken together, our data strongly implicate
Gfi1 in the maintenance of established T cell malignancies, their
ability to kill secondary hosts, and potentially in improving
therapy.
Maintenance of B Cell Lymphoma Is Dependent on Gfi1
To test whether other lymphoid malignancies were also depen-
dent on Gfi1, we used Em-Myc transgenic mice, which develop
clonal B cell lymphomas (Adams et al., 1985). Loss of Gfi1 did
not affect the latency, incidence, or pathology of tumor initia-
tion (Figures 3A and 3B) but completely blocked the ability of(G) Top view shows Notch1DCT;Gfi1+/+ and Notch1DCT;Gfi1/ mice that were m
curve.
(H and I) Spleen weights (H) and flow cytometric analysis (I, top panels) an
Notch1DCT;Gfi1/ (n = 3) tumors.
(J) Top view shows Gfi1+/+ and Gfi1/ newborn mice that were injected with MM
(K) Thymic tumor cell numbers of Notch1DCT-induced tumors.
(L) Flow cytometric analysis (top panels) and histological section (bottom panels
Scale bars, 50 mm. Vertical line ( j ) in all Kaplan-Meier curves indicates censored
**p < 0.01, ***p < 0.001.
See also Figure S1 and Table S1.
Clymphoma to kill secondary recipients (Figure S3A). Thus,
similar to the T cell models, Gfi1 is required for robust tumori-
genesis. To determine whether Gfi1 is required for B cell
lymphoma maintenance, we used an inducible model (Zhu
et al., 2006) to delete Gfi1f/f after a lymphoma had formed.
Although pIpC injection had no effect on progression of
disease in Gfi1f/f;Em-Myc mice, it led to tumor regression and
a significant reduction of leukemic blasts in the peripheral
blood of Mx1-Cre;Gfi1f/f;Em-Myc mice (Figures 3C–3E and
S3B), suggesting that Gfi1 is indeed necessary to maintain
a B cell lymphoma. Similar to the results with our T-ALL
models, loss of Gfi1 significantly improved the outcome of
Gfi1/;Em-Myc mice treated with sublethal irradiation and
BMT after detection of a tumor, whereas Gfi1+/+;Em-Myc
animals died of tumor relapse (Figure 3F). These data suggest
that targeting Gfi1 could also be beneficial for treating B cell
lymphoma.
Gfi1 Integrates the Cellular Transcriptional Response to
DNA Damage/p53 Induction
To investigate how loss of Gfi1 induces tumor regression, we
compared gene expression profiles of T cell leukemia from two
different models (Figures 2A and 2D) upon inducible deletion
of Gfi1 (Figure 4A). Gene Set Enrichment Analysis (GSEA) (Sub-
ramanian et al., 2005) demonstrated significant deregulation
of multiple key leukemic pathways, including cell-cycle progres-
sion, NFkB signaling, and basal transcription among others
(Table S2; data not shown). Normal thymocytes do not disappear
upon loss of Gfi1 as the tumors do. Therefore, to identify mech-
anisms that might explain tumor regression, we focused on
those pathways that were similarly deregulated in both ENU
and Notch1DCT-induced tumors from Gfi1/ and Gfi1+/+ mice
but were not enriched in normal nonmalignant Gfi1/ versus
Gfi1+/+ thymocytes. We noticed a striking number of shared
GSEA signatures that included deregulated p53 signaling, DNA
damage/repair pathways, and a proapoptotic response (Figures
4B and 4C; Table S2), suggesting that an accelerated cell death
program might be initiated in tumor cells that lack Gfi1.
An emerging concept proposes that oncogenic signaling
induces uncoordinated cell division, generating collapsed
replication forks and DNA double-strand breaks, which in turn
initiate a DNA damage response, activating p53 and inducing
apoptosis. Therefore, tumor cells must counteract cell death in
order to survive (Bartek et al., 2007; Bartkova et al., 2007; Di
Micco et al., 2006; Halazonetis et al., 2008). In agreement with
this theory, leukemic cells from our tumor models displayed
increased levels of phosphorylated H2AX (gH2AX), indicating
DNA double-strand breaks, and higher levels of spontaneousonitored for tumor development and survival. Bottom view is a Kaplan-Meier
d histological sections (I, bottom panels) of Notch1DCT;Gfi1+/+ (n = 7) and
LV. Bottom view is a Kaplan-Meier curve.
) of MMLV-induced Gfi1+/+ versus Gfi1/ tumors.
mice. Mean and mean ± SEM are shown unless stated otherwise. *p < 0.05,
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Figure 2. Gfi1 Is Required for T Cell Leukemia Maintenance
(A) Top view shows Gfi1f/f orMx1-Cre+;Gfi1f/fmice that were treated with ENU and subsequently with pIpC. Bottom view is a Kaplan-Meier curve. Inset presents
PCR analysis of the Gfi1 locus in control tissues and in representative tumors (T) for Gfi1 flox and excised (D) alleles.
(B) Top view showsGfi1f/f orMx1-Cre+;Gfi1f/fmice that were treated with ENU and followed for tumors by ultrasound (US). Next, mice were treated with pIpC, and
tumor development was determined by ultrasound. Bottom view is representative ultrasound images. Scale bars, 20 mm.
(legend continued on next page)
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Gfi1 and Lymphoid Leukemiaapoptosis than untransformed thymocytes (Figures 4D–4F). We
also noted that the number of apoptotic cells was further
increased in those tumors whereGfi1was inducibly deleted (Fig-
ure 4F). Additionally, when we irradiated Gfi1/ leukemic cells,
we observed decreased survival compared to Gfi1+/+ tumors
(Figures 4G). Finally, when we overexpressed Bcl2 in Tal1-trans-
formed T cell lines, counterselection of the dominant-negative
mutant Gfi1N382S was either absent or delayed (compare Fig-
ure 4H to Figure 2H). These data demonstrate that Gfi1 is
required in lymphoid tumors to counter DNA damage-induced
death and suggest that DNA damage/p53-induced signals are
dominant effectors of Gfi1 loss-of-function apoptotic pheno-
types in T-ALL.
In contrast toGfi1-deleted tumors,Gfi1/ thymocytes display
only mildly increased levels of apoptosis of c-Kit+ subsets
(compared to Gfi1+/+) (Yu¨cel et al., 2003). In agreement with
this observation, we noted that whereas GSEA of gene expres-
sion data of Gfi1/ versus Gfi1+/+thymocytes is enriched for
apoptotic signatures, the DNA damage and p53 signatures,
which drive the execution of apoptosis, were not enriched
(Figures 5A and 5B). Thus, we hypothesized that the introduc-
tion of a DNA damage signal (inherent to tumors) to Gfi1/
thymocytes may elicit the same increased apoptotic phenotype
in thymocytes that was found in tumors. Indeed, gene expres-
sion analysis revealed that a comparison between g-irradiated
(to induce DNA damage) Gfi1/ versus Gfi1+/+thymocytes
recapitulated the exaggerated Gfi1/ GSEA DNA damage and
p53 signatures found in leukemia cells (compare Figures 4B
and 5B). Moreover, DNA damage induced by daunorubicin,
etoposide, or by various doses of g irradiation resulted in signif-
icantly decreased Gfi1/ thymocyte survival and mitochondrial
potential (Figures S4A–S4E). Although Gfi1/ thymocytes
showed similar levels of gH2AX, p53 induction, and p53
phosphorylation compared to Gfi1+/+ controls (Figures S4F
and S4G), Gfi1/ thymocytes displayed increased cleaved
caspase-3 and PARP (Figures S4H and S4I). These data indicate
that Gfi1 antagonizes DNA damage-induced apoptotic path-
ways downstream of DNA damage detection but upstream of
caspase and PARP1 cleavage.
To analyze this in more detail, the expression of cell death-
associated p53 targets such as Bax, Pmaip1 (Noxa), and Bbc3
(Puma) was tested and found to be further induced in irradiated
Gfi1/ thymocytes compared to Gfi1+/+ controls (Figure 5C).(C) Change of thymic surface area before and after treatment with pIpC for mice
(D) Top view shows Notch1DCT;Gfi1f/f or Notch1DCT;Mx1-Cre+;Gfi1f/f mice that w
development. Upon appearance of a mass, mice were injected with pIpC and
a Kaplan-Meier curve. Inset presents a PCR analysis of allele excision (D).
(E) Representative ultrasound images of tumors before and after pIpC injection.
(F) Change of thymic surface area before and after treatment with pIpC (see E).
(G) Top view shows Gfi1f/f tumors or tumors that had one Gfi1 allele deleted (Mx
treated with pIpC. Bottom view is a Kaplan-Meier curve.
(H) T-ALL cell lines 5151, 5046, and 5010 were transduced with retrovirus vector
time by FACS and normalized to the level at 48 hr. One of three representative e
(I) Top view shows Gfi1f/f orMx1-Cre+;Gfi1f/f mice that were injected with ENU. F
irradiated, and transplanted with wild-type CD45.1 BM cells, then followed for surv
morbidity unrelated to leukemia.
(J) BM of mice in (I) at the end of observation was examined for contribution of t
Vertical line ( j ) in all Kaplan-Meier curves indicates censored mice. Mean and m
See also Figure S2.
CThese genes appear to be direct Gfi1 targets because interroga-
tion of Gfi1 ChIP-seq data showed enriched Gfi1 binding in the
regulatory regions of Bax, Pmaip1, and Bbc3 compared to IgG
controls (Figure 5D). These data suggest that Gfi1 co-occupies
p53-responsive genes and regulates their expression. Interest-
ingly, significant p53 binding to these same Gfi1-bound regions
within the promoters (underscored in Figure 5D) of Bax, Pmaip1,
and Bbc3 was observed in thymocytes after induction of p53 by
irradiation (Figure 5E). To assess whether Gfi1 and p53 globally
regulate the expression of proapoptotic p53 effector genes, we
examined the leading edge of the GSEA Gfi1/-irradiated
thymocyte signature and found that >70% of the apoptotic
genes were in fact proapoptotic effectors (Figure S4J). More-
over, combining the gene expression and ChIP-seq analyses
revealed that Gfi1 occupies 55 of 77 p53-effector genes
(>70%) deregulated in irradiatedGfi1/ thymocytes (Figure 5F).
We next validated the ChIP-seq data with ChIP-qPCR using
primer sets for 14 of the 55 genes. These genes were (1) occu-
pied by Gfi1 according to ChIP-seq data with reads over 100
compared to Ig controls, (2) at least 1.5-fold differentially ex-
pressed between Gfi1/ and Gfi1+/+ thymocytes after irradia-
tion, and (3) known p53 effector genes according to empirically
tested data in the Molecular Signature Database (MSigDB).
ChIP-qPCR confirmed binding of Gfi1 in irradiated thymocytes
with an enrichment of >1.5-fold in 10 of the 14 genes tested, sug-
gested Gfi1 binding in 3 genes with an enrichment of 1.3–1.5,
and demonstrated little to no binding in only 1 of the 14 primer
sets tested (Figure S4K). Co-occupation of the same loci by
Gfi1 and p53 was found in the majority of genes tested (9 of
14, Figure S4L). A time-dependent analysis on 4 of the 14 loci
(Bax, Pmaip1, Bbc3, and Cdkn1a) revealed that a co-occupation
by Gfi1 and p53 is maintained over time but that p53 occupation
clearly dominates at 120 min after the initial DNA damage signal
over Gfi1 (Figure S4M). This suggests that during the immediate
response after DNA damage, Gfi1 and p53 coregulate target
genes, but if the DNA damage signal persists, a p53-dominated
regulation prevails.
We investigated the involvement of the p53-activated
apoptosis pathway in Gfi1/ thymocyte survival after DNA
damage. To do so, we deleted Trp53 or overexpressed Bcl2
and found that either condition completely rescued the exag-
gerated Gfi1/ thymocyte apoptosis upon DNA damage
signaling (Figure 5G). Further investigation into the underlying(see B).
ere treated with ENU and subsequently monitored by ultrasound for tumor (T)
followed for tumor progression or regression by ultrasound. Bottom view is
Scale bars, 20 mm.
1-Cre+;Gfi1f/D) were transplanted into CD45.1 recipient mice, which were then
s expressing Gfi1N382S and dsRed or dsRed alone. dsRed was measured over
xperiments is shown.
ifty days later, they were treated with pIpC. Twenty-eight days later, they were
ival. Bottom view is a Kaplan-Meier curve. OneGfi1f/fmouse was sacrificed for
he CD45.2 (host BM) and CD45.1 (donor BM).
ean ± SEM are shown unless stated otherwise. *p < 0.05, **p < 0.01.
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Figure 3. Gfi1 Is Required for Maintenance of B Cell Lymphoma
(A) Top view shows Gfi1+/+;Em-Myc and Gfi1/;Em-Myc mice that were monitored for tumor development and survival. Bottom view is a Kaplan-Meier
curve.
(B) Flow cytometric analysis (top) and histological sections (bottom) of Em-Myc-induced Gfi1+/+ and Gfi1/ tumors. Scale bars, 50 mm.
(C) Top view showsMx1-Cre+;Gfi1f/f;Em-Myc andGfi1f/f;Em-Mycmice that were observed by ultrasound for appearance of B cell lymphoma. Upon appearance of
a mass, mice were injected with pIpC and monitored for tumor progression and survival. Bottom view is a Kaplan-Meier curve.
(D) Representative ultrasound images of tumors before and after pIpC injection. Scale bars, 20 mm.
(E) Change of tumor surface area (left) before and after treatment with pIpC for mice with the indicated genotypes as well as cellularity of mediastinal tumor after
treatment (right).
(F) Top view shows Gfi1+/+;Em-Myc and Gfi1/;Em-Myc animals that were observed until enlarged lymph nodes evidenced tumor development, then they were
irradiated and transplanted with CD45.1 BM cells and monitored for survival. Bottom view is a Kaplan-Meier curve.
Vertical line ( j ) in all Kaplan-Meier curves indicates censored mice. Mean and mean ± SEM are shown unless stated otherwise. *p < 0.05.
See also Figure S3.
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Figure 4. Gfi1 Mediates DNA Damage and p53 Signaling to Control Apoptosis
(A) Unsupervised hierarchical clustering of the averaged normalized Log2 gene expression values from ENU (n = 3) or ENU/Notch1
DCT (n = 2)-induced T-ALL
arising inGfi1f/f (wild-type, WT) orMx1-Cre+;Gfi1f/f (knockout, KO) pIpC-treated mice (ENUWT, n = 3; ENU KO, n = 3; ENU/Notch1DCTWT, n = 2; ENU/Notch1DCT
KO, n = 2).
(B) GSEA butterfly plots for pathways related to DNA damage, p53 signaling, or apoptosis found in both ENU- and Notch1DCT-initiated tumor signatures from (A).
(legend continued on next page)
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interact in transfected cells and in irradiated thymocytes
(Figures 5H and 5I) and that Gfi1 was able to repress p53-
mediated transcriptional activation of a model reporter gene
(Figure 5J). Notably, methylation of p53 at K372 leads to
increased stability of chromatin-bound p53 and to the activa-
tion of p53 target genes, whereas demethylation of K372 has
an inhibitory effect on p53 (West and Gozani, 2011). Immuno-
precipitation and immunoblot experiments with Gfi1+/+ and
Gfi1/ thymocytes showed that absence of Gfi1 leads to
a substantial increase of p53-K372me, regardless of irradiation
(Figure 5K). Moreover, thymocytes from knockin mice express-
ing only a Gfi1P2A mutant (Fiolka et al., 2006) that lacks the
ability to bind LSD1 (Saleque et al., 2007) also displayed
a substantial increase of p53-K372me (Figure 5L). These data
suggest that Gfi1 restricts p53 activity through Gfi1 SNAG-
dependent cofactor recruitment and p53 demethylation
(Figure 5M).
Targeting GFI1 in Human ALL Leads to Tumor Death
To test whether Gfi1 could be a suitable target for therapy of
human leukemia, we used human T-ALL cell lines and reduced
Gfi1 expression either by transduction of previously described
shRNA-expressing lentiviral vectors (Velu et al., 2009) or Vivo-
Morpholinos (Morcos et al., 2008) specifically designed against
GFI1. In both cases, reduction of Gfi1 impeded the growth of
T-ALL cell lines, which correlated with a higher level of apoptosis
(Figures 6A–6C and S5A–S5C), suggesting that T-ALL is sensi-
tive to the induction of apoptosis. When we used the pan-Bcl2
inhibitors Obatoclax and ABT-263 on three independent T-ALL
lines, we observed IC50 values approximately 10-fold lower
than those observed in acute myeloid leukemia (AML), where
the use of these drugs is currently in clinical trials (Figure 6D).
Inhibition of Gfi1 further increased the efficiency of both Obato-
clax treatment (Figure 6E) and radiation therapy (Figure S5D). To
demonstrate the contribution of p53 to Gfi1 loss-of-function
apoptosis, we used Vivo-Morpholinos to first antagonize p53
expression then Gfi1 expression. We observed a significant
decrease in the ability of the Gfi1 Vivo-Morpholinos to induce
apoptosis after p53 Vivo-Morpholino pretreatment (Figure S5E).
Similar results were obtained using p53-targeting shRNA
lentiviruses followed by Gfi1 Vivo-Morpholino treatment (data
not shown).
Next, we examined Gfi1 inhibition in primary patient
samples. Due to the significant limitations of in vitro systems
to support primary T-ALL cell survival, we transplanted primary
patient specimens into immune-deficient Nod/Scid/IL2Rg/(C) Classification of genes in the leading edge of the GSEA apoptosis signature
(D and E) Determination of gH2AX levels in normal tissue as well as in B and T
performed. Scale bars, 50 mm.
(F) Level of spontaneous apoptosis in the indicated tissues and tumors before an
Gfi1+/+, n = 4; Gfi1f/f, n = 13; Gfi1D/D, n = 4.
(G)Gfi1+/+ (n = 7),Gfi1/ andGfi1f/D (one constitutive Gfi1 KO tumor and two tum
tumor cells and Gfi1+/+;Em-Myc+ (n = 7), and Gfi1/;Em-Myc+ (n = 3) lymphomas
FACS.
(H) T-ALL cell lines 5151, 5046, and 5010 were transduced with retrovirus vectors
and dsRed or dsRed alone. dsRed was measured over time by FACS and norma
Mean and mean ± SEM are shown unless stated otherwise. *p < 0.05, **p < 0.01
See also Table S2.
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nos is a viable approach to treat leukemia. The cells were al-
lowed to engraft and expand for 4 days before the mice
were injected with Vivo-Morpholinos over a 3 week period
and monitored for survival. Gfi1 Vivo-Morpholino-treated
animals showed a trend toward increased survival after only
three injections (Figures S5F–S5I). We repeated the assay
with samples from a patient who failed to respond to cur-
rent therapies but increased the treatment frequency. When
control morpholino (NT)-treated mice became moribund, we
analyzed the tissues of all of the transplanted mice for the
presence of human T-ALL cells. Targeting Gfi1 significantly
impeded the expansion of the human leukemia in the BM,
peripheral blood, and the spleen of the transplanted NSG
mice (Figures 6F–6H), whereas treatment of healthy mice
with the same dosing regimen did not lead to adverse effects
(Figure S5J).
DISCUSSION
Important roles for Gfi1 in normal lymphoid development and
acceleration of murine T cell leukemia have previously been es-
tablished (Blyth et al., 2001; Chakraborty et al., 2008; Dabrow-
ska et al., 2009; Gilks et al., 1993; Scheijen et al., 1997;
Schmidt et al., 1996; Uren et al., 2008; Yu¨cel et al., 2003).
Yet, questions remained whether Gfi1 was required for the
development or maintenance of human lymphoid leukemia. In
the current study, we found that ablation of Gfi1 leads to
regression of already established murine lymphoid neoplasms
occurring through the induction of p53-dependent apoptotic
pathways. Our results indicate that leukemic cells in general
require Gfi1 because the ablation of Gfi1 led to lymphoid tumor
regression and host survival independently of the transforming
pathway or tumor etiology. It is thus conceivable that Gfi1 is an
‘‘oncorequisite’’ factor, a normal cellular protein upon which
malignant cells uniquely depend for their survival. This offers
a different paradigm for cancer therapeutics and suggests
that normal cellular proteins, independent of their mutation
status in human tumors, can be excellent targets for clinical
intervention.
Our findings are surprising given the recently identified
function of Gfi1 in myeloproliferative disease (MPD) and AML,
where Gfi1 loss of function derepresses HoxA9, Meis1, and
Pbx1, and can cooperate with other oncogenic lesions to trans-
form myeloid progenitors (Horman et al., 2009). Furthermore,
a SNP in the human GFI1 deregulates HOXA9 expression and
increases the risk for human AML by 60% (Khandanpour et al.,in (B) as Proapoptotic, Antiapoptotic, or Context Dependent.
cell leukemia by FACS (D) and immunofluorescence (E). One experiment was
d after Gfi1 deletion. T-ALL: Gfi1+/+, n = 4; Gfi1f/f, n = 17; Gfi1D/D, n = 5. B-ALL:
ors, in which Gfi1 has been deleted with more than 50% excision, n = 3), thymic
were explanted and irradiated (6 Gy), and examined for Annexin V staining by
MSCV-Bcl-2, expanded, and then transduced with vectors encoding Gfi1N382S
lized to the level at 48 hr. One of three representative experiments is shown.
.
Figure 5. Gfi1 Restricts p53-Dependent Induction of Apoptosis
(A) Unsupervised hierarchical clustering of the averaged normalized Log2 gene expression values from Gfi1
+/+ (WT) and Gfi1/ (KO) thymocytes with or without
irradiation (Gfi1+/+ control, n = 2; Gfi1/ control, n = 2; Gfi1+/+ irradiated, n = 3; Gfi1/ irradiated, n = 3).
(B) GSEA butterfly plots for pathways related to DNA damage, p53 signaling, or apoptosis enriched in Gfi1-deficient tumors (Figure 4B) that emerge in Gfi1/
T cells only after irradiation.
(legend continued on next page)
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incisively define a role for Gfi1 in human AML. HoxA9 signaling
is present in mixed-lineage leukemia but is active in less than
10%of patients with T-ALL (Ferrando et al., 2002). Thus, patients
with rare HoxA9-active T-ALL may not benefit from receiving
Gfi1-targeting therapies. Therefore, careful molecular pathology
will likely be important to stratify patients for Gfi1-targeted
therapeutics.
Recent work suggested that oncogenic signaling in general
causes uncoordinated cell division resulting in collapsed replica-
tion forks and the initiation of p53-dependent DNA damage
responses causing cell death (Halazonetis et al., 2008; Bartek
et al., 2007; Bartkova et al., 2007; Di Micco et al., 2006). Tumor
cells have to counteract this ‘‘oncogenic stress’’ signal to avoid
cell death, for instance by mutating TP53. However, TP53muta-
tions are rare in T-ALL; hence, leukemic cells have to devise
other measures to circumvent apoptosis. Our data offer an
explanation as to how lymphoid malignancies can overcome
p53 activation and why they are dependent on Gfi1. We propose
that DNA damage, initiated by oncogenic stress during malig-
nant transformation, induces p53 activity. High Gfi1-expressing
subclones can thus be selected during transformation to enable
global restriction of p53-mediated apoptosis. Gfi1 exerts this
function by (1) co-occupying p53 target genes such as Bax,
Pmaip1, and Bbc3; (2) binding to p53-bound transcriptional
complexes; and (3) limiting the methylation of p53 at K372
thereby restricting the activity of p53 and the activation of p53
target genes.
The function of Gfi1 to limit p53-K372 methylation (p53-K369
in murine cells) (Kurash et al., 2008) appears to be dependent
on its ability to bind SNAG-dependent cofactors such as
LSD1. It is known that demethylation of p53 at K370 is medi-
ated by LSD1 and prevents p53 association with coactivators
such as p53BP1 (Huang et al., 2007). We propose that
leukemic cells use a Gfi1-LSD1 or a Gfi1-SNAG-dependent
cofactor complex to demethylate p53 at K372, which prevents(C) Expression of Bax, Pmaip1 (Noxa), and Bbc3 (Puma) in Gfi1+/+ and Gfi1/ t
at least two experiments is shown. The numbers above the bars represent the m
(D) Peaks across the Bax, Pmaip1, and Bbc3 loci from Gfi1 ChIP-seq of murine
MLL-ENL expression vector (GSE31657).
(E) ChIP of p53 using primers from Gfi1-bound regions (underscored with arrow in
mean and SD of the fold difference compared to IgG control from one experime
(F) Log2 values of the fold change of the irradiated versus unirradiated gene expre
Gfi1+/+ and Gfi1/ thymocytes. Gfi1-bound (identified in D) p53 target genes are
(G) Percentage of live Gfi1+/+;Trp53+/+, Gfi1/;Trp53+/+,Gfi1+/+;Trp53/, and Gfi
live Gfi1+/+, Gfi1/, Gfi1+/+;Vav-Bcl2, and Gfi1/;Vav-Bcl2 thymocytes after ex
(H) Immunoblot of total-cell lysate (left) and immunoprecipitation (right) were perfo
irradiated 293T cells transfected as indicated with FLAG-tagged Gfi1 constructs
(I) Immunoblot of total-cell lysate (left) and immunoprecipitation using either Gfi1 o
(Ser15) antibody on lysates from irradiated thymocytes cells. One representative
(J) Reporter expression assay using the Bax promoter and various amounts (mg)
(K) Thymocytes from the indicatedmice were irradiated or left untreated. After 30 m
p53 antibody, then immunoblotted with an anti-p53 antibody. p53 and tubulin in to
is shown.
(L) Thymocyte nuclear extracts from the indicated mouse strains were immunopr
with an anti-p53 antibody. Input control shows the level of Gfi1 in thymocytes fro
experiment out of at least two experiments is shown.
(M) Schematic representation showingmethylated p53 binds to DNA and robustly
of p53 targets tethers a Gfi1 SNAG-dependent cofactor, which demethylates p5
Mean and ± mean SEM are shown unless stated otherwise. *p < 0.05, **p < 0.01
See also Figure S4.
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However, we cannot exclude the possibility that loss of
Gfi1-SNAG-dependent transcriptional repression leads to the
activation of factors, which may directly affect p53 activation/
methylation status. In either case, ablation of Gfi1 leads to an
accumulation of more active methylated p53, to a more effi-
cient transactivation of proapoptotic p53 target genes, and as
a consequence, to accelerated cell death. Several independent
lines of evidence support this notion including reporter gene
assays, ChIP-seq data, biochemical analyses, and expression
data and offer a mechanistic explanation why Gfi1 ablation
leads to regression of murine lymphomas and causes an
inhibition of primary human T-ALL cell expansion in immune-
deficient mice.
Our findings have direct implications for current ALL treat-
ments, which consist of chemotherapy and irradiation. Both
are nonspecific and highly toxic, damaging host and tumor
tissues. These therapies function mainly through the induction
of DNA damage and the initiation of p53-dependent DNA
damage response pathways that cause cell death. Even when
effective, patients can suffer dramatic side effects from standard
ALL treatments. Therefore, reducing chemotherapeutic or
irradiation dose and thus their side effects while maintaining
their efficacy would directly benefit patients. The main result
from our study suggests that this goal can be achieved by
inhibiting the function of Gfi1 in patients with T-ALL because
ablation of Gfi1 accelerates p53-induced cell death in leukemic
cells. According to our data, leukemic cells lacking Gfi1 will
be more sensitive to DNA damage-inducing chemo- or irradia-
tion therapy and undergo accelerated apoptosis. It is thus con-
ceivable that targeting Gfi1 will not only significantly improve
response rates but may in particular allow lower effective
doses of chemotherapeutic agents or irradiation. In summary,
our findings suggest that Gfi1 represents an Achilles’ heel of
lymphoid leukemias, and our approach to target Gfi1 may
soon move to clinical trials.hymocytes before and after irradiation. One representative experiment out of
ean values of the measurements.
hematopoietic progenitor cells immortalized by retroviral transduction of an
D) of Bax, Pmaip1, and Bbc3 before and after irradiation. Represented are the
nt with three technical repeats.
ssion values of all genes (left) or 1.5-fold differentially regulated (right) between
shown in red.
1/;Trp53/ thymocytes after ex vivo g irradiation (left, n = 3). Percentage of
vivo g irradiation (right, n = 3).
rmed using p53, phospho- p53, or Gfi1 antibodies on lysates from untreated or
. One representative experiment from at least two experiments is shown.
r an isotype control (actin) antibody (right) were performed using phospho-p53
experiment from at least two experiments is shown.
of transfected vectors encoding p53 or Gfi1.
in, total-cell lysates were immunoprecipitated with an anti-mono-methyl K372
tal-cell lysates are also shown. One experiment out of at least two experiments
ecipitated with an anti-mono-methyl K372 p53 antibody, then immunoblotted
m Gfi1+/+, Gfi1/, and Gfi1P2A/P2A mice and the loading control LaminB. One
activates the expression of target genes (a), andGfi1 co-occupancy of a subset
3 to dampen the expression of p53 target gene (b).
.
Figure 6. Gfi1 as a Target to Treat Human Leukemia
(A) HBP-ALL cells were transduced with Venus-marked shRNA-expressing lentiviral vectors targeting Gfi1 (shGfi1, dotted line) or nontargeting control
(shNT, solid line). Expression of Venus was measured by FACS 72 hr posttransduction, which was set as 1, and subsequent measurements were taken by FACS
over a 5 week period and normalized to the first reading, p = 0.058.
(B) Growth of HBP-ALL cells treated with Gfi1 or NT Vivo-Morpholinos (VM) as measured by WST assay for 48 hr. Inset shows immunoblot for Gfi1 in HBP-ALL
cells treated with NT or Gfi1-VM (4 mM) for 16 hr.
(C) Annexin V and PI staining of HBP-ALL cells after 16 hr of Gfi1 or NT VM treatment (4 mM).
(D) Growth of T-ALL cell lines treated with indicated doses of the Obatoclax as measured by WST assay for 48 hr.
(E) Gfi1 knockdown was combined with Obatoclax treatment (200 nM), and growth was measured by WST assay for 48 hr. One representative experiment is
shown; experiments were repeated two to three times (A–E).
(F) Top view shows primary patient T-ALL samples that were transplanted in NSGmice and then mice were injected with Gfi1 or NT VM three times per week for
3 weeks. Bottom view is a FACS analysis of human CD45 and human CD3 of NT (n = 2) or Gfi1-treated (n = 3) mice.
(legend continued on next page)
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All other experimental procedures can be found in the Supplemental
Information.
Mice
LckCre+, Mx1-Cre+, C57BL/6, CD45.1, Trp53/, and NSG mice were ob-
tained from The Jackson Laboratory (Bar Harbor, ME, USA). Regarding other
mouse strains, please refer to the Supplemental Experimental Procedures.
Mice were housed in either single ventilated cages with top filters or microiso-
lator cages. The Institutional Animal Care, Use and Ethical Committees
responsible for Cincinnati Children’s Hospital Medical Center (CCHMC), the
Institut de Recherches Cliniques de Montre´al (IRCM), and University Clinic
Essen (UKE) reviewed and approved all animal experimentation.
Xenograft Transplants and Morpholino Treatment
Diagnostic patient samples were obtained after informed consent according
to Helsinki declaration and with approval from the institutional review boards
at the IRCM, CCHMC, and UKE for the described experiments. One million
T-ALL cells were transplanted (i.v.) into NSG mice that were injected 4 days
later (i.v.) with Vivo-Morpholinos (Gene Tools) as described in Figures 6 and
S5 with 25 nM of control (‘‘NT-VM,’’ 50-CCTCTTACCTCAGTTACAATT TATA-
30 ) or Gfi1-specific (‘‘Gfi1-VM,’’ 50-ATGGTGGTCCGGCACTTTCCCCACT-30)
Vivo-Morpholinos per injection.
In Vivo Deletion of Gfi1 and Ultrasound Observation
Gfi1f/f or RosaCreERT2 Gfi1f/f mice were injected (i.p.) with 1 mg OHT
(Sigma-Aldrich) dissolved in 100 ml of corn oil the first 5 days following
transplantation. Gfi1f/f or Mx1-Cre+;Gfi1f/f mice were either injected (i.p.)
4 weeks after the last ENU injection or 3 days after the transplantation
of the tumor cells with 500 mg pIpC (Sigma-Aldrich) seven times every
other day. PCR validation of in vivo deletion was performed as pre-
viously described (Horman et al., 2009). Ultrasound observation was per-
formed on anesthetized mice, and thymic tumors were measured using the
Visualsonic ultrasound machine and the Vev0770 imaging software (Toronto).
A tumor was called present if the thymic surface area measured in the
horizontal and sagittal plane was larger than 8 mm2 because average thymic
surface of age-matched, untreated Gfi1f/f control mice is 4 mm2, and if
the tumor exhibited growth of more than 50% during the last 2 weeks of
observation.
Statistics
GraphPad Prism software (GraphPad Software, La Jolla, CA, USA) was used
for most statistical analysis. Kaplan-Meier curves were analyzed using log
rank tests. A p value %0.05 was considered significant for all analyses.
Differences in incidences of leukemia or lymphoma among the different groups
were determined using Fisher’s exact test. Two-tailed unpaired Student’s
t tests were used to calculate the differences in the gene expression of patient
data,WBC, and spleenweights of transplantedmice, aswell as the differences
in cell number or tumors in ENU and MMLV-treated mice. The Mann-Whitney
U test was used to determine significance in counterselection assays.
Two-way ANOVAs were used to calculate significance of Vivo-Morpholino
dose-responsive curves. Differences in Annexin V staining of Bcl2-transgenic
Gfi1/ mice and Trp53p53/Gfi1/ were calculated using one-way
ANOVAs. GSEA FDR Q values <0.25 were used as a cutoff for enriched
signatures.
ACCESSION NUMBERS
Array data are accessible under GEO accession number GSE32910.(G) Quantification of total human CD45+ cells in the blood and spleen from mice
(H) Cytospins of the BM from mice in (F). Scale bars, 50 mm.
Mean and mean ± SEM are shown unless stated otherwise. *p < 0.05, **p < 0.01
See also Figure S5.
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